Psilocybin does not show up on a standard DOT drug test. The federally mandated 5-panel urine screen used for DOT safety-sensitive employees checks for marijuana, cocaine, opioids, amphetamines, and PCP, and psilocybin is not on that list. That is not the whole answer, though. Psilocybin is a Schedule I controlled substance under federal law, and DOT rules separately bar safety-sensitive workers from using any Schedule I drug, detectable on the panel or not.
What the DOT 5-Panel Screens For
DOT testing follows 49 CFR Part 40 and runs the same panel across every mode: trucking, aviation, rail, transit, and pipeline. The panel covers five categories, with confirmation testing for 14 individual drugs inside those categories.1US Department of Transportation. DOT 5 Panel Notice
- Marijuana (THC): initial screening at 50 ng/mL, confirmed at 15 ng/mL
- Cocaine: tested through the metabolite benzoylecgonine, initial screening at 150 ng/mL
- Opioids: codeine, morphine, heroin (6-AM), hydrocodone, hydromorphone, oxycodone, oxymorphone
- Amphetamines: amphetamine, methamphetamine, MDMA, MDA
- Phencyclidine (PCP): initial screening at 25 ng/mL
Each analyte has its own cutoff, and a specimen has to hit or exceed the threshold on both the initial immunoassay and a confirmation test before the lab reports a positive.2eCFR. 49 CFR Part 40 Section 40.85 Psilocybin, psilocin, and other hallucinogens outside PCP simply are not analytes the lab is looking for.
Why the Panel Result Isn’t the End of the Analysis
The Controlled Substances Act lists both psilocybin and psilocin as Schedule I substances, in the same schedule as heroin and LSD.3Office of the Law Revision Counsel. 21 USC 812 – Schedules of Controlled Substances For commercial motor vehicle drivers, federal regulations prohibit reporting for duty or remaining on duty while using any Schedule I substance, and that prohibition covers every Schedule I drug, not only the ones the panel can flag.4eCFR. 49 CFR Part 382 Section 382.213 – Controlled Substance Use If an employer has actual knowledge of controlled substance use, that employer cannot allow the driver to perform safety-sensitive work. The FAA, FRA, FTA, and PHMSA have parallel prohibitions for their regulated workers.
So the panel is one enforcement mechanism. The underlying legal prohibition stands on its own.
Reasonable Suspicion Testing
DOT rules give employers another tool that doesn’t depend on the panel detecting psilocybin. If a trained supervisor observes specific signs of impairment based on appearance, behavior, speech, or body odors, the employer can require a controlled substances test on reasonable suspicion.5eCFR. 49 CFR Part 382 Section 382.307 – Reasonable Suspicion Testing The supervisor making that call has to have completed training on the signs and symptoms of drug and alcohol use.
The reasonable suspicion test itself is still the standard 5-panel, so psilocybin still won’t appear on the result. But the documented observations of impairment, combined with the Schedule I prohibition, can support removal from safety-sensitive duties and discipline even without a positive lab report.
Non-DOT Employer Testing Can Include Psilocybin
Many DOT-regulated employers run their own company drug testing on top of the federal minimum. These non-DOT tests can be customized to screen for substances the federal panel misses, and expanded panels covering hallucinogens are commercially available. A non-DOT test follows the employer’s own policy, not 49 CFR Part 40 procedures.
A non-DOT positive cannot be reported as a DOT violation, and the DOT test itself cannot be expanded to include substances outside the federally mandated panel. But a non-DOT positive for psilocybin can still trigger consequences under company policy, including termination.
State Decriminalization Doesn’t Change the Rules
Several states and cities have decriminalized or deprioritized enforcement of psilocybin possession, and Oregon has a regulated therapeutic use framework. None of that reaches DOT-regulated employment. Federal transportation regulations preempt state and local drug laws for safety-sensitive positions.6US Department of Transportation. Procedures for Transportation Workplace Drug and Alcohol Testing Programs The DOT has made the same point repeatedly about marijuana, and the same logic applies to psilocybin. If you hold a CDL, fly, work on the railroad, or fill any other DOT safety-sensitive role, federal law is what governs your obligations.
What Happens if You Do Test Positive or Refuse
If a confirmed positive reaches the Medical Review Officer, the MRO contacts you to check for a legitimate medical explanation, such as a valid prescription. If none holds up, the MRO verifies the result as positive. Your employer then has to immediately remove you from all safety-sensitive duties on receipt of the verified result, with no waiting period.7eCFR. 49 CFR 40.23 – What Actions Do Employers Take After Receiving Verified Test Results
Getting back to safety-sensitive work means completing the full return-to-duty process: evaluation by a Substance Abuse Professional, whatever education or treatment the SAP prescribes, and a negative return-to-duty test. Initial SAP evaluations typically cost $250 to $600, and the return-to-duty test generally runs $75 to $200, though prices vary by provider. After returning, you face follow-up testing for at least 12 months, with a minimum of six tests in that first year. The SAP can extend follow-up testing for up to 60 months.
A refusal to test carries the same consequences as a verified positive. And the definition of refusal is broader than most people assume: not appearing at the collection site within a reasonable time, leaving before the process is complete, failing to provide enough urine without a medical explanation, refusing observation when required, or admitting the specimen was tampered with all count.8U.S. Department of Transportation. DOT Rule 49 CFR Part 40 Section 40.191
The short version for a DOT safety-sensitive worker weighing this question: the standard panel won’t flag shrooms, but the federal prohibition on Schedule I drug use, reasonable suspicion testing, and employer non-DOT panels all reach the same conduct. Passing the 5-panel is not the same as being in compliance.